THE US Food and Drug Administration added a serious "boxed" warning on the prescribing information for Amgen's drug Prolia, known to treat bone loss, as it increases the risk of severely low calcium levels in certain patients.
The warning comes after the health regulator in 2022 started a review into the risk of very low blood calcium in patients with advanced chronic kidney disease, particularly ones on dialysis and Prolia.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Jan 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Jan 24
